Astec Lifesciences Ltd (ASTEC) — shareholding pattern, promoter holding, financials and share price
About Astec Lifesciences Ltd (ASTEC)
Astec Lifesciences Ltd operates in the Pesticides & Agrochemicals industry, within the Chemicals sector. It trades on the NSE as ASTEC and on the BSE under scrip code 533138. Its ISIN is INE563J01010.
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries. Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B). [1] [2] [3]
Astec LifeSciences Ltd is primarily engaged in the manufacturing of agrochemicals and pharmaceutical intermediates, offering active ingredients, intermediates, and formulations mainly for crop protection and API manufacturers.
The company expanded its operations significantly over the years, reaching an installed production capacity of 3150 MT, as of FY 2009-10. This expansion included acquiring new plots and establishing multiple manufacturing units.
Listed peers in Pesticides & Agrochemicals: Bharat Rasayan Ltd, Insecticides India Ltd, India Pesticides Ltd, Punjab Chemicals & Crop Protection Ltd, Meghmani Organics Ltd, Dharmaj Crop Guard Ltd.
Valuation & Returns
10 Jul 2026At ₹686.15 a share on 10 Jul 2026, Astec Lifesciences Ltd (ASTEC) was valued at a price-to-book of 6.51x on a book value of ₹105.35 per share as of Mar 2025. Solomo computes return on equity of -34.46% and return on capital employed of -5.89% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 22.12x
- P/B
- 6.51x
- EPS (TTM)
- ₹-36.3
- Book value / share
- ₹105.35
- ROE
- -34.46%
- ROCE
- -5.89%
- ROA
- -9.18%
- Debt / equity
- 2.36x
- Dividend yield
- 0%
- EBITDA margin
- -0.35%
- 52-week range
- ₹512.35 – ₹940.45
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Astec Lifesciences Ltd (ASTEC) reported revenue of ₹448 crore, net profit of ₹-81 crore and earnings per share of ₹-36.32. That compares with revenue of ₹381 crore and net profit of ₹-135 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹158.62 crore and net profit ₹-7.75 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 677 | 628 | 458 | 381 | 448 |
| Net profit (₹ cr) | 90 | 26 | -47 | -135 | -81 |
| EPS (₹) | 40.12 | 11.41 | -20.95 | -60.16 | -36.32 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.52% | -6.10% | -17.40% | -16.78% |
| Profit growth | - | - | - | -187.29% |
| Stock price CAGR | 7% | -13% | -19% | -24% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.96% of Astec Lifesciences Ltd (ASTEC) (down 0.01 pp QoQ), foreign institutional investors (FII) hold 0.01% and domestic institutional investors (DII) hold 3.33%. Market capitalisation was ₹1,529 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2010.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND 2.36%, AJAY KUMAR AGGARWAL 1.05%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.96% | - | 0.01% | 3.33% | 28.04% |
| Mar 2026 | 71.97% | - | 0.02% | 3.34% | 28.03% |
| Dec 2025 | 71.97% | - | 0.04% | 3.17% | 28.03% |
| Sep 2025 | 72.42% | - | 0% | 4.01% | 27.58% |
| Jun 2025 | 70.87% | - | 0.02% | 4.26% | 29.13% |
| Mar 2025 | 70.87% | - | 0.25% | 4.34% | 29.13% |
| Dec 2024 | 66.75% | - | 1.2% | 5.41% | 33.25% |
| Sep 2024 | 66.75% | - | 0.53% | 4.51% | 33.25% |